- Home
- YRD vs ANL Comparison
YRD vs ANL Comparison
Compare YRD & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | YRD | ANL |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | China | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.4M | 293.4M |
| IPO Year | 2015 | 2022 |
Fundamental Metrics
Financial Performance| Metric | YRD | ANL |
|---|---|---|
| Price | $2.01 | $7.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 70.0K | ★ 196.2K |
| Earning Date | 03-19-2026 | 04-20-2026 |
| Dividend Yield | ★ 21.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $0.88 |
| 52 Week High | $7.68 | $12.09 |
Technical Indicators
Market Signals| Indicator | YRD | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 15.47 | 39.77 |
| Support Level | N/A | $1.36 |
| Resistance Level | $4.40 | $9.98 |
| Average True Range (ATR) | 0.20 | 0.89 |
| MACD | -0.16 | -0.33 |
| Stochastic Oscillator | 1.57 | 13.03 |
Price Performance
Historical ComparisonAbout YRD Yiren Digital Ltd.
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.